TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10774766

Group type: EXPERIMENTAL
Intervention: Saturated fat (SF) meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Monounsaturated fat (MUFA) meal
Number of subjects: 10
Study: 7721921

Group type: EXPERIMENTAL
Intervention: Continuous retrograde normothermic
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intermittent retrograde hypothermic
Number of subjects: 20
Study: 1790147

Group type: EXPERIMENTAL
Intervention: Recombinant gamma-interferon (rGIFN) as a 2-h intravenous infusion daily x 5 every other week at a starting dose of 4.0 x 10(6) IU/m2/day (arm I)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Recombinant gamma-interferon (rGIFN) as a 24-h continuous intravenous infusion daily x 5 every month at a starting dose of 2.6 x 10(6) IU/m2/day (arm II)
Number of subjects: 50
Study: 7029989

Group type: EXPERIMENTAL
Intervention: salmon calcitonin (100 MRC) plus arginine
Number of subjects: 6

Group type: COMPARATOR
Intervention: basal conditions
Number of subjects: 6
Study: 31079079

Group type: EXPERIMENTAL
Intervention: Geriatric assessment and management for 6 months
Number of subjects: 350

Group type: COMPARATOR
Intervention: Usual oncologic care
Number of subjects: 350
Study: 27807735

Group type: EXPERIMENTAL
Intervention: 25 mg/kg body weight oral GHB before going to bed
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 25
Study: 25504449

Group type: EXPERIMENTAL
Intervention: iTAB (two-way text messaging system)
Number of subjects: 25

Group type: COMPARATOR
Intervention: CTRL (active comparison)
Number of subjects: 25
Study: 23958221

Group type: EXPERIMENTAL
Intervention: Induction therapy based on risk assessment and therapy response in HR+/HER2- patients
Number of subjects: 4936

Group type: EXPERIMENTAL
Intervention: Short induction treatment for endocrine therapy
Number of subjects: 4936

Group type: EXPERIMENTAL
Intervention: Dynamic testing of early therapy response
Number of subjects: 4936
Study: 21362312

Group type: EXPERIMENTAL
Intervention: Shensongyangxin (SSYX) capsule
Number of subjects: 859

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 859

Group type: COMPARATOR
Intervention: Mexiletine tablet
Number of subjects: 859
Study: 19340640

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 16905632

Group type: EXPERIMENTAL
Intervention: New generation antipsychotics (amisulpride)
Number of subjects: 3725

Group type: EXPERIMENTAL
Intervention: New generation antipsychotics (olanzapine)
Number of subjects: 3725

Group type: COMPARATOR
Intervention: Conventional antipsychotics (CAs)
Number of subjects: 3725
Study: 15070934

Group type: EXPERIMENTAL
Intervention: Cabergoline treatment for 24 months
Number of subjects: 51
Study: 11455866

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg rocuronium
Number of subjects: 48

Group type: COMPARATOR
Intervention: 0.075 mg/kg vecuronium
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 9646264

Group type: EXPERIMENTAL
Intervention: High-performance centres (randomized > or = 10 patients)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Remaining centres (randomized < 10 patients)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Centres with > or = 2 high-performance centres
Number of subjects: 564

Group type: COMPARATOR
Intervention: Remaining centres of the same countries
Number of subjects: 564

Group type: COMPARATOR
Intervention: Centres that randomized 0-1 patient
Number of subjects: 564
Study: 7518975

Group type: COMPARATOR
Intervention: CsA
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 121
Study: 2310658

Group type: EXPERIMENTAL
Intervention: 10% glycerol in saline (500 ml over 4 h on 6 consecutive days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control treatment with saline
Number of subjects: 35
Study: 476223

Group type: EXPERIMENTAL
Intervention: d-Amphetamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31875775

Group type: EXPERIMENTAL
Intervention: Novel therapeutic game controller and telerehabilitation system
Number of subjects: 7
Study: 30790566

Group type: EXPERIMENTAL
Intervention: Amniotic fluid index and single deepest pocket measurements
Number of subjects: 1719
Study: 28512921

Group type: EXPERIMENTAL
Intervention: Integrated Bipolar Parenting Intervention (IBPI) plus treatment as usual (TAU)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 97
Study: 25557952

Group type: EXPERIMENTAL
Intervention: Simeprevir (150 mg/day) and Sofosbuvir (400 mg/day)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Peginterferon alfa 2b (1.5 mcg/kg/wk), Ribavirin (1000-1200 mg/day), and Sofosbuvir (400 mg/day)
Number of subjects: 82
Study: 23181690

Group type: EXPERIMENTAL
Intervention: Patients with CKD
Number of subjects: 10271

Group type: COMPARATOR
Intervention: Patients without CKD
Number of subjects: 10271

Group type: EXPERIMENTAL
Intervention: Patients with stage 1 CKD
Number of subjects: 10271

Group type: EXPERIMENTAL
Intervention: Patients with stage 5 CKD
Number of subjects: 10271

Group type: EXPERIMENTAL
Intervention: Uncontrolled hypertensive patients with CKD
Number of subjects: 10271
Study: 21324086

Group type: COMPARATOR
Intervention: Traditional OC regimen (21/7)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Extended-cycle OC regimen (24/4)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both OC regimens
Number of subjects: 115
Study: 19475577

Group type: EXPERIMENTAL
Intervention: Fibrin glue (FG) as interpositioning layer
Number of subjects: 40

Group type: COMPARATOR
Intervention: Martius flap (MF) as interpositioning layer
Number of subjects: 40
Study: 17261212

Group type: COMPARATOR
Intervention: Lecture-based approach
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Case/problem-based learning discussion
Number of subjects: 54
Study: 15564951

Group type: EXPERIMENTAL
Intervention: Prophylactic epidural blood patch with 20 ml autologous blood
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sham patch
Number of subjects: 64
Study: 11481299

Group type: EXPERIMENTAL
Intervention: Amoxycillin (AMX) for 10 days
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Co-amoxiclav (AMC) for 10 days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no antibiotic therapy)
Number of subjects: 45
Study: 9668732

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 3

Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 3
Study: 7921858

Group type: EXPERIMENTAL
Intervention: Esmolol 200 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Esmolol 100 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 3292578

Group type: EXPERIMENTAL
Intervention: Muscle stretching treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no treatment mentioned)
Number of subjects: 34
Study: 4980112

Group type: EXPERIMENTAL
Intervention: Tetracycline phosphate complex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Demethylchlortetracycline hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methacycline hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate
Number of subjects: 0
Study: 31713184

Group type: EXPERIMENTAL
Intervention: Calcitriol 0.25 μg three times daily from transplantation to day 30
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 29216289

Group type: COMPARATOR
Intervention: Unloaded
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 7% of body mass
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15% of body mass
Number of subjects: 12
Study: 25744852

Group type: EXPERIMENTAL
Intervention: Positive airway pressure at 15 cmH2O plus conventional chest physiotherapy
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Conventional chest physiotherapy plus non‐therapeutic positive airway pressure at 4 cmH2O
Number of subjects: 156

Group type: COMPARATOR
Intervention: Non‐therapeutic positive airway pressure at 4 cmH2O
Number of subjects: 156
Study: 24284618

Group type: EXPERIMENTAL
Intervention: Sublingual nucleotides (50 mg/day) for 14 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21766553

Group type: EXPERIMENTAL
Intervention: L-isoleucine (2 g/L)-added ORS
Number of subjects: 50

Group type: COMPARATOR
Intervention: ORS without L-isoleucine (control)
Number of subjects: 50
Study: 19383056

Group type: EXPERIMENTAL
Intervention: Standard care plus an eight week stroke specific self-management education group program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard care plus a six week generic chronic condition self-management group education program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 16829490

Group type: EXPERIMENTAL
Intervention: Repetition of associative lists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Separate recognition tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated lists
Number of subjects: 0
Study: 15324105

Group type: EXPERIMENTAL
Intervention: Progressive physical activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stable angina pectoris
Number of subjects: 0
Study: 11132743

Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (Voluven)
Number of subjects: 59

Group type: COMPARATOR
Intervention: HES 200/0.5 (pentastarch)
Number of subjects: 59
Study: 9296895

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 90
Study: 8380295

Group type: EXPERIMENTAL
Intervention: NWTS-1 treatment regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NWTS-2 treatment regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NWTS-3 treatment regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with specimen weight 550 g or greater
Number of subjects: 0
Study: 3946161

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (0.25 mg/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (0.25 mg/kg) in patients receiving long-term propranolol (120 to 240 mg/day)
Number of subjects: 16
Study: 30216377

Group type: EXPERIMENTAL
Intervention: GE S8 2D-SWE
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Samsung RS80A
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transient Elastography (TE)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 5 vs. 10 measurements
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Gender comparison (Males vs. Females)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Age and BMI groups
Number of subjects: 100
Study: 27903263

Group type: EXPERIMENTAL
Intervention: Muscle Response Testing (MRT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intuition
Number of subjects: 68

Group type: COMPARATOR
Intervention: Chance
Number of subjects: 68
Study: 25133792

Group type: EXPERIMENTAL
Intervention: Music (N=20)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Maternal voice (N=20)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (N=22)
Number of subjects: 62
Study: 23104611

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP), specifically autologous conditioned plasma (ACP), 5.5 mL, 4 intra-articular injections
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA), 20 mg/2 mL, 4 intra-articular injections
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA), 20 mg/2 mL, 4 intra-articular injections (specifically for grade III gonarthrosis)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP), specifically autologous conditioned plasma (ACP), 5.5 mL, 4 intra-articular injections (specifically for grade III gonarthrosis)
Number of subjects: 120
Study: 19815457

Group type: EXPERIMENTAL
Intervention: Dynamic aerobic endurance training at lower intensity (33% of heart rate reserve) for 10 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Dynamic aerobic endurance training at higher intensity (66% of heart rate reserve) for 10 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sedentary period between training periods
Number of subjects: 39
Study: 18441005

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori 'test and treat' strategy (UBT)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Prompt endoscopy (OGD)
Number of subjects: 432
Study: 16234118

Group type: EXPERIMENTAL
Intervention: LAMK I
Number of subjects: 64

Group type: COMPARATOR
Intervention: FOE
Number of subjects: 64
Study: 12670813

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (100 mg)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Morphine (3 mg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (100 mg) + Morphine (3 mg)
Number of subjects: 65
Study: 10392225

Group type: EXPERIMENTAL
Intervention: Blood sample obtained from normal saline lock with no blood discarded
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Blood sample obtained from normal saline lock after discarding 2 times the dead space (3 mL)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Venipuncture blood sample
Number of subjects: 32
Study: 8913124

Group type: EXPERIMENTAL
Intervention: Outpatient haemodilution (HD) regimen (packed cell volume of <0.35, 12 weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no haemodilution)
Number of subjects: 59
Study: 1907535

Group type: COMPARATOR
Intervention: TFT eyedrops
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: BVDU eyedrops
Number of subjects: 50
Study: 6824608

Group type: EXPERIMENTAL
Intervention: Oral iron supplementation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31666344

Group type: EXPERIMENTAL
Intervention: R-HDS (high-dose chemotherapy with rituximab and autograft)
Number of subjects: 134

Group type: COMPARATOR
Intervention: CHOP-R (conventional chemotherapy with rituximab)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Complete remission
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Molecular remission
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: No disease recurrence
Number of subjects: 134
Study: 29888778

Group type: EXPERIMENTAL
Intervention: Low-fat yoghurt supplemented with rooster comb extract (RCE)
Number of subjects: 148
Study: 26848185

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 4949

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 4949
Study: 24256500

Group type: EXPERIMENTAL
Intervention: Severe economic loss (job or housing loss)
Number of subjects: 5382

Group type: COMPARATOR
Intervention: Moderate economic loss (loss of retirement savings, reduced work hours/wages, trouble paying rent/mortgage)
Number of subjects: 5382

Group type: EXPERIMENTAL
Intervention: Retirement loss, reduced hours/wages, and job loss (for women)
Number of subjects: 5382

Group type: EXPERIMENTAL
Intervention: Job loss and housing problems (for men)
Number of subjects: 5382

Group type: EXPERIMENTAL
Intervention: Partial or complete job loss and housing problems (for middle-aged Americans)
Number of subjects: 5382

Group type: EXPERIMENTAL
Intervention: Loss of retirement savings (for older adults)
Number of subjects: 5382

Group type: COMPARATOR
Intervention: Young adults (18 to 29)
Number of subjects: 5382
Study: 22036059

Group type: EXPERIMENTAL
Intervention: Intrathecal dexamethasone (8 mg) with intrathecal morphine (0.2 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution with intrathecal morphine 0.2 mg)
Number of subjects: 120
Study: 20118683

Group type: EXPERIMENTAL
Intervention: 2-dose priming with PHiD-CV
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: 3-dose priming with PHiD-CV
Number of subjects: 351
Study: 17397003

Group type: EXPERIMENTAL
Intervention: Resiquimod 0.01% gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study: 14697444

Group type: EXPERIMENTAL
Intervention: 3M Cavilon No‐Sting Barrier Film
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sorbolene cream (10% glycerin)
Number of subjects: 61
Study: 11943968

Group type: EXPERIMENTAL
Intervention: Skills-based firearm safety program
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control Group (no intervention)
Number of subjects: 70
Study: 9817336

Group type: EXPERIMENTAL
Intervention: Repeat biopsy screening
Number of subjects: 984

Group type: COMPARATOR
Intervention: Primary biopsy screening
Number of subjects: 984
Study: 8745496

Group type: EXPERIMENTAL
Intervention: Fluorometry technique (UFMI)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Fluorometry technique (UMI)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Group II (no MAS, but amniotic fluid with meconium stain)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Group III (normal control)
Number of subjects: 68
Study: 2670647

Group type: EXPERIMENTAL
Intervention: Famotidine (1 tablet of 40 mg at night)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Ranitidine (2 tablets of 150 mg at night)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Famotidine and Ranitidine
Number of subjects: 143
Study: 805649

Group type: EXPERIMENTAL
Intervention: Aqueous procaine penicillin G, 4.8 million units IM in one session plus 1.0 g probenecide
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Tetracycline HCI, 9 g over 4 days
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Trimethoprim, 80 mg-sulfamethoxazole, 400 mg (TMP-SMX) six tablets once daily for 3 days
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: TMP-SMX, six tablets twice on 1 day at a 6-hour interval
Number of subjects: 327
Study: 31720928

Group type: EXPERIMENTAL
Intervention: Chimeric nanobodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic combinatorial library
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Library clones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preliminary RD selection
Number of subjects: 0
Study: 30371882

Group type: EXPERIMENTAL
Intervention: Modified Battlefield Acupuncture
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo Auricular Acupuncture
Number of subjects: 233

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 233
Study: 28945869

Group type: EXPERIMENTAL
Intervention: Prednisolone (37.5 mg/d)
Number of subjects: 19
Study: 25449342

Group type: EXPERIMENTAL
Intervention: CC with audio-visual feedback device
Number of subjects: 63

Group type: COMPARATOR
Intervention: CC without audio-visual feedback device
Number of subjects: 63
Study: 23219471

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-containing COC
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 21480984

Group type: EXPERIMENTAL
Intervention: Oral morphine (0.5 mg/kg) with sublingual midazolam (0.2 mg/kg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Oral morphine (0.5 mg/kg) with sublingual placebo
Number of subjects: 58
Study: 18477268

Group type: EXPERIMENTAL
Intervention: Mannitol (0.5 g x kg(‐1) in pump prime)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hartmann's solution (control)
Number of subjects: 40
Study: 16302286

Group type: EXPERIMENTAL
Intervention: Eu‐glycaemic condition
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hyperglycaemic condition
Number of subjects: 8
Study: 15232337

Group type: EXPERIMENTAL
Intervention: Naltrexone alone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Naltrexone in combination with clonazepam
Number of subjects: 23

Group type: COMPARATOR
Intervention: Clonazepam alone
Number of subjects: 23
Study: 11382108

Group type: EXPERIMENTAL
Intervention: Oral feeding started in the 1st postoperative week
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Early postoperative oral feeding
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Type of resection (extended laryngectomy with partial pharyngectomy)
Number of subjects: 42
Study: 9203777

Group type: EXPERIMENTAL
Intervention: 10% maleic acid etching for 15 seconds
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10% maleic acid etching for 30 seconds
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10% maleic acid etching for 60 seconds
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study: 8202968

Group type: EXPERIMENTAL
Intervention: Silent infarct presence
Number of subjects: 1132

Group type: EXPERIMENTAL
Intervention: Infarct size
Number of subjects: 1132

Group type: EXPERIMENTAL
Intervention: Distribution of silent infarcts
Number of subjects: 1132

Group type: EXPERIMENTAL
Intervention: Factors associated with silent infarction
Number of subjects: 1132

Group type: COMPARATOR
Intervention: Comparison with transient ischemic attacks
Number of subjects: 1132
Study: 3118746

Group type: EXPERIMENTAL
Intervention: Nebulized atropine methonitrate (anticholinergic bronchodilator)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Metaproterenol hydrochloride (beta-adrenergic bronchodilator)
Number of subjects: 12
Study: 29354934

Group type: EXPERIMENTAL
Intervention: Acupoint massage (1 min at one acupoint, once a day for 5 days, starting from the 3rd day after operation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine nursing after operation, guiding maternal breastfeeding and postpartum health education (Control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acupoint massage
Number of subjects: 60
Study: 27894521

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compomer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polycarboxylate cement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no orthodontic treatment)
Number of subjects: 0
Study: 26323489

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 4 µg kg(‐1) (Group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 3 µg kg(‐1) (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 23622911

Group type: EXPERIMENTAL
Intervention: Catalytic iron (CI) levels at baseline
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Highest quartile of CI levels
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Contrast nephropathy
Number of subjects: 806